Read + Share
Chen X, Huang J, Xu N, Fan Z, et al. A phase 2 study of sorafenib combined with conventional therapies in refractory
central nervous system leukemia. Cancer 2022 Mar 22. doi: 10.1002/cncr.34182.
PMID: 35315510
|
 |
|
Chen X, Huang J, Xu N, Fan Z, et al. A phase 2 study of sorafenib combined with conventional therapies in refractory
central nervous system leukemia. Cancer 2022 Mar 22. doi: 10.1002/cncr.34182.
PMID: 35315510
|
|
|
|